PDF herunterladen
Semin Thromb Hemost 2016; 42(02): 125-132
DOI: 10.1055/s-0035-1569068
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Judicious Use of Recombinant Factor VIIa

Lawrence Tim Goodnough
1   Department of Pathology and Medicine, Stanford University, Stanford, California
,
Jerrold H. Levy
2   Department of Anesthesiology and Critical Care, Duke University, Durham, North Carolina
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
02. Februar 2016 (online)

    Lizenzen und Reprints

Abstract

Recombinant activated factor VIIa (rFVIIa) is a prohemostatic agent initially approved for use in hemophilia patients with inhibitors and recently for Glanzmann thrombasthenia. Despite its approval indications, rFVIIa has also been used for a diverse range of off-label indications to treat bleeding related to traumatic injury, major hemorrhage following surgery, intracranial hemorrhage, and for uncontrolled bleeding as a prothrombotic hemostatic agent. Despite its off-label use, the benefit of rFVIIa in most nonhemophilia settings remains uncertain as the majority of clinical trials have not consistently demonstrated beneficial effects as determined by reduced bleeding, decreased blood product utilization, or have not demonstrated a mortality benefit. As with any prohemostatic agent, the risk of thromboembolic events is increased when rFVIIa is used off-label. Pooled data from randomized nonhemophilia studies report an increased risk in the elderly for arterial thromboses, although most individual trials have been underpowered to determine adverse thrombotic events. The causes of thrombotic adverse events associated with off-label use of rFVIIa may be due to an increased risk of adverse events due to critical illness or due to higher doses of rFVIIa used in off-label trials. Without clearly supportive data, physicians should consider risk versus benefit and exercise restraint using rFVIIa in off-label settings. Further, evidence-based guidelines should be developed by professional organizations, and additional randomized controlled clinical trials are needed to further assess the efficacy and safety of off-label rFVIIa use.

Keywords

recombinant activated factor VIIa - hemorrhage - coagulopathy - prothrombotic - surgery - thrombosis
 

  • References

  • 1 Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71 (6) 1836-1841
    CrossrefPubMedGoogle Scholar
  • 2 Hedner U, Glazer S, Pingel K , et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2 (8621) 1193
    PubMedGoogle Scholar
  • 3 Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008; 100 (4) 557-562
    PubMedGoogle Scholar
  • 4 Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol 2001; 8 (5) 312-318
    CrossrefPubMedGoogle Scholar
  • 5 Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104 (13) 3858-3864
    CrossrefPubMedGoogle Scholar
  • 6 Sheikh AY, Hill CC, Goodnough LT, Leung LL, Fischbein MP. Open aortic valve replacement in a patient with Glanzmann's thrombasthenia: a multidisciplinary strategy to minimize perioperative bleeding. Transfusion 2014; 54 (2) 300-305
    PubMedGoogle Scholar
  • 7 Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011; 154 (8) 516-522
    CrossrefPubMedGoogle Scholar
  • 8 Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44 (9) 1325-1331
    CrossrefPubMedGoogle Scholar
  • 9 Yank V, Tuohy CV, Logan AC , et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154 (8) 529-540
    CrossrefPubMedGoogle Scholar
  • 10 Mayer SA, Brun NC, Begtrup K , et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352 (8) 777-785
    CrossrefPubMedGoogle Scholar
  • 11 Mayer SA, Brun NC, Begtrup K , et al; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358 (20) 2127-2137
    CrossrefPubMedGoogle Scholar
  • 12 Novo Nordisk. NovoSeven (recombinant) package insert. Available at: http://www.factorviia.com/pi.pdf . Accessed Nov 30, 2015
    PubMedGoogle Scholar
  • 13 Boffard KD, Riou B, Warren B , et al; NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59 (1) 8-15 , discussion 15–18
    CrossrefPubMedGoogle Scholar
  • 14 Narayan RK, Maas AI, Marshall LF, Servadei F, Skolnick BE, Tillinger MN ; rFVIIa Traumatic ICH Study Group. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery 2008; 62 (4) 776-786 , discussion 786–788
    CrossrefPubMedGoogle Scholar
  • 15 Gill R, Herbertson M, Vuylsteke A , et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120 (1) 21-27
    CrossrefPubMedGoogle Scholar
  • 16 Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95 (5) 596-602
    CrossrefPubMedGoogle Scholar
  • 17 Ekert H, Brizard C, Eyers R, Cochrane A, Henning R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 2006; 17 (5) 389-395
    CrossrefPubMedGoogle Scholar
  • 18 Bosch J, Thabut D, Bendtsen F , et al; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127 (4) 1123-1130
    CrossrefPubMedGoogle Scholar
  • 19 Bosch J, Thabut D, Albillos A , et al; International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008; 47 (5) 1604-1614
    CrossrefPubMedGoogle Scholar
  • 20 Lodge JP, Jonas S, Jones RM , et al; rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11 (8) 973-979
    CrossrefPubMedGoogle Scholar
  • 21 Planinsic RM, van der Meer J, Testa G , et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005; 11 (8) 895-900
    CrossrefPubMedGoogle Scholar
  • 22 Liu JP, Chen T, Wang J , et al. Hemorrhagic features and the application of recombinant activated factor VII in liver transplantation. Journal of Clinical Rehabilitative Tissue Engineering Research. 2009; 13 (18) 3580-3584
    PubMedGoogle Scholar
  • 23 Pugliese F, Ruberto F, Summonti D , et al. Activated recombinant factor VII in orthotopic liver transplantation. Transplant Proc 2007; 39 (6) 1883-1885
    CrossrefPubMedGoogle Scholar
  • 24 Pihusch M, Bacigalupo A, Szer J , et al; F7BMT-1360 Trial Investigators. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3 (9) 1935-1944
    CrossrefPubMedGoogle Scholar
  • 25 Shander A, Goodnough LT, Ratko T , et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven®) therapy. Pharmacy & Therapeutics 2005; 30: 644-658
    PubMedGoogle Scholar
  • 26 Novo Nordisk. Evaluation of recombinant factor VIIa in patients with severe bleeding (CONTROL). Clinical Trials website: https://clinicaltrials.gov/ct2/show/NCT00184548 . Accessed November 30, 2015
    PubMedGoogle Scholar
  • 27 Bélisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996; 62 (6) 1908-1917
    CrossrefPubMedGoogle Scholar
  • 28 Karkouti K, McCluskey SA, Syed S, Pazaratz C, Poonawala H, Crowther MA. The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesth Analg 2010; 110 (6) 1533-1540
    CrossrefPubMedGoogle Scholar
  • 29 Schols SE, Lancé MD, Feijge MA , et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 2010; 103 (2) 318-328
    PubMedGoogle Scholar
  • 30 Rao VK, Lobato RL, Bartlett B , et al. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery. J Cardiothorac Vasc Anesth 2014; 28 (5) 1221-1226
    CrossrefPubMedGoogle Scholar
  • 31 Omar HR, Enten G, Karlnoski R, Ching YH, Mangar D, Camporesi EM. Recombinant activated factor VII significantly reduces transfusion requirements in cardiothoracic surgery. Drugs R D 2015; 15 (2) 187-194
    CrossrefPubMedGoogle Scholar
  • 32 Alfirevic A, Duncan A, You J, Lober C, Soltesz E. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg 2014; 98 (2) 618-624
    CrossrefPubMedGoogle Scholar
  • 33 Freeman WD, Brott TG, Barrett KM , et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 79 (12) 1495-1500
    CrossrefPubMedGoogle Scholar
  • 34 Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth 2008; 20 (4) 276-279
    CrossrefPubMedGoogle Scholar
  • 35 Robinson MT, Rabinstein AA, Meschia JF, Freeman WD. Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system. Stroke 2010; 41 (7) 1459-1463
    CrossrefPubMedGoogle Scholar
  • 36 Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137 (11) 884-888
    CrossrefPubMedGoogle Scholar
  • 37 Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology (Am Soc Hematol Educ Program) 2008; 36-38
    PubMedGoogle Scholar
  • 38 Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 2008; 122 (1) 117-123
    CrossrefPubMedGoogle Scholar
  • 39 Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010; 116 (5) 693-701
    CrossrefPubMedGoogle Scholar
  • 40 Morgenstern LB, Hemphill III JC, Anderson C , et al; American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41 (9) 2108-2129
    CrossrefPubMedGoogle Scholar
  • 41 Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG. Safety indicators for inpatient and outpatient oral anticoagulant care: recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol 2007; 136 (1) 26-29
    CrossrefPubMedGoogle Scholar
  • 42 Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am Soc Hematol Educ Program 2010; 2010: 153-159
    CrossrefPubMedGoogle Scholar
  • 43 O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295 (3) 293-298
    CrossrefPubMedGoogle Scholar
  • 44 Thomas GO, Dutton RP, Hemlock B , et al. Thromboembolic complications associated with factor VIIa administration. J Trauma 2007; 62 (3) 564-569
    CrossrefPubMedGoogle Scholar
  • 45 Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363 (19) 1791-1800
    CrossrefPubMedGoogle Scholar
  • 46 Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14 (5) 898-902
    CrossrefPubMedGoogle Scholar
  • 47 Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2 (6) 899-909
    CrossrefPubMedGoogle Scholar
  • 48 Birchall J, Stanworth SJ, Duffy MR, Doree CJ, Hyde C. Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia. Transfus Med Rev 2008; 22 (3) 177-187
    CrossrefPubMedGoogle Scholar
  • 49 Hsia CC, Zurawska JH, Tong MZ, Eckert K, McAlister VC, Chin-Yee IH. Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events. Transfus Med 2009; 19 (1) 43-49
    CrossrefPubMedGoogle Scholar
  • 50 Diringer MN, Skolnick BE, Mayer SA , et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010; 41 (1) 48-53
    CrossrefPubMedGoogle Scholar
  • 51 Warren O, Mandal K, Hadjianastassiou V , et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007; 83 (2) 707-714
    CrossrefPubMedGoogle Scholar
  • 52 Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002; 124 (4) 852-854
    CrossrefPubMedGoogle Scholar
  • 53 Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012; 3: CD005011
    PubMedGoogle Scholar
  • 54 Lin Y, Moltzan CJ, Anderson DR ; National Advisory Committee on Blood and Blood Products. The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework. Transfus Med 2012; 22 (6) 383-394
    CrossrefPubMedGoogle Scholar
  • 55 Ferraris VA, Brown JR, Despotis GJ , et al; Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion; International Consortium for Evidence Based Perfusion. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91 (3) 944-982
    CrossrefPubMedGoogle Scholar
  • 56 Karkouti K, Levy JH. Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg 2011; 113 (4) 711-712
    CrossrefPubMedGoogle Scholar
  • 57 Mazzeffi M, Szlam F, Jakubowski JA, Tanaka KA, Sugidachi A, Levy JH. In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. Thromb Res 2013; 132 (1) 106-111
    CrossrefPubMedGoogle Scholar
  • 58 Szlam F, Tanaka KA, Rumph B, Bolliger D, Levy JH. In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition. Thromb Haemost 2010; 103 (4) 863-865
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 59 Karkouti K, Beattie WS, Wijeysundera DN , et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005; 45 (1) 26-34
    CrossrefPubMedGoogle Scholar
  • 60 Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118 (6) 1466-1474
    CrossrefPubMedGoogle Scholar